About Us | Contact Us |        

Managing the Patient with Metastatic Melanoma: A Comprehensive, Evidence-Based Approach

Hematology-Oncology
Curriculum:
Managing the Patient with Metastatic Melanoma: A Comprehensive, Evidence-Based Approach
Credits:
1 AMA PRA Category 1 Credit(s)™
Launch Date:
January 08, 2016
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Hematology-oncology physicians, nurse practitioners, and physician assistants

Relevant Terms:

Metastatic melanoma

Keith T. Flaherty, MD

Keith T. Flaherty, MD
Associate Professor of Medicine
Harvard Medical School
Director, Henri and Belinda Termeer Center for Targeted Therapies
Director, Clinical Research
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Keith T. Flaherty, MD, is associate professor of medicine at Harvard Medical School as well as director of the Henri and Belinda Termeer Center for Targeted Therapies and director of clinical research at Massachusetts General Hospital Cancer Center in Boston.

Dr. Flaherty received a bachelor of science from Yale University and medical degree from Johns Hopkins University. He trained in internal medicine at Brigham and Women's Hospital and completed a fellowship in medical oncology at the University of Pennsylvania, where he continued on as faculty before moving to Massachusetts General Hospital and Harvard Medical School.

Dr. Flaherty is the deputy chair for Biomarker Science and chair of the Developmental Therapeutics Committee for the Eastern Cooperative Oncology Group. He is a senior editor for Clinical Cancer Research. He is a charter member of the National Cancer Institute Developmental Therapeutics Study Section. Additionally, Dr. Flaherty is president-elect of the Society for Melanoma Research and is on the board of trustees for the Cancer Education Consortium.

With a career-long focus in therapeutic research in advanced melanoma, Dr. Flaherty has led the investigation of many of the first molecular targeted therapies brought forward in light of emerging molecular biology discoveries regarding the somatic genetic underpinnings of melanoma. He has also contributed greatly to the clinical development and associated translational research with numerous investigational targeted therapies, including the first effective targeted therapies for metastatic melanoma. His work has been published in a number of peer-reviewed publications, including Clinical Cancer Research, New England Journal of Medicine, Nature, and Lancet Oncology, and he is on the editorial boards of Oncologist, Journal of Translational Medicine, and Journal of Clinical Oncology, and he is a senior editor for Clinical Cancer Research and scientific editor for Cancer Discovery.

Michael Davies, MD, PhD

Michael Davies, MD, PhD
Associate Professor
Department of Melanoma Medical Oncology
Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Michael Davies, MD, PhD, is deputy chairman and associate professor in the department of Melanoma Medical Oncology, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, Houston, with a joint appointment in the department of Systems Biology.
 
Dr. Davies earned his medical and doctorate degrees from the University of Texas Health Science Center in Houston. He completed his clinical residency training in internal medicine at Massachusetts General Hospital in Boston and his medical oncology fellowship at the University of Texas MD Anderson Cancer Center.
 
Dr. Davies is a physician-scientist whose research utilizes integrated approaches to study the regulation and clinical significance of oncogenic signaling networks in cancer, particularly in therapeutic resistance and the molecular pathogenesis brain metastases. He is a member of the American Society of Clinical Oncology (ASCO), American Association for Cancer Research, Society for Melanoma Research, and SWOG.
 
Dr. Davies has been the principal investigator of both individual and team science peer-reviewed grants from several organizations, including the National Cancer Institute, ASCO, Melanoma Research Alliance, and Melanoma Research Foundation. He has served as the principal investigator of several clinical trials for patients with metastatic melanoma and has authored or co-authored research in peer-reviewed journals including Cell, Cancer Cell, Cancer Research, and Clinical Cancer Research. Dr. Davies is a member of the Melanoma Research Foundation Breakthrough Consortium and the International Melanoma Working Group, and he is the co-director of the MD Anderson Melanoma Moon Shot Team and the MD Anderson MelCore, the largest clinically annotated melanoma tissue bank in the world.

Janice M. Mehnert, MD

Janice M. Mehnert, MD
Director, Developmental Therapeutics Unit
Rutgers Cancer Institute of New Jersey
Associate Professor of Medicine
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey

Janice M. Mehnert, MD, is director of the Developmental Therapeutics Unit at Rutgers Cancer Institute of New Jersey and a member of the Melanoma and Soft Tissue Oncology Program. She is also an associate professor of medicine at Rutgers Robert Wood Johnson Medical School.
 
Dr. Mehnert received her medical degree from Rutgers Robert Wood Johnson Medical School. She completed her residency training in internal medicine at the Mount Sinai Hospital, New York, followed by a fellowship in medical oncology and hematology at the Yale Cancer Center. She began her career at Rutgers Cancer Institute of New Jersey/Rutgers Robert Wood Johnson Medical School.
 
At a national level, Dr. Mehnert is part of the Melanoma Committee of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network, where she works with other investigators to develop clinical trials for patients with melanoma. She is a member of the American Society Clinical Oncology Education Committee for Melanoma and Skin Cancers. Her clinical research focuses on novel therapies for all types of tumors, especially melanoma and sarcoma, and involves the development of both targeted and immunotherapies. Her broad clinical research experience spans industry-sponsored, investigator-initiated, and cooperative group studies.
 
Dr. Mehnert is the author or co-author of multiple peer-reviewed articles and book chapters and has been awarded numerous peer-reviewed national and private foundation grants to support her work. She has published in such prestigious authorities as Cancer Discovery, Journal of Clinical Oncology, and Clinical Cancer Research, having served on the editorial board of the latter.
1. Select appropriate treatments for melanoma based on their mechanism of action and efficacy and safety data
2. Utilize evidence-based treatment recommendations to devise personalized treatment regimens for patients with metastatic melanoma
3. Appropriately screen for and manage side effects and psychosocial concerns in patients with metastatic melanoma
4. Utilize a variety of strategies including patient education, patient engagement, and shared decision-making to improve outcomes in patients with metastatic melanoma

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and RMEI, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
 
Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
 
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
  • Keith T. Flaherty, MD, has affiliations with GlaxoSmithKline, Merck, Novartis, and Roche (Consulting Fees).
  • Michael Davies, MD, PhD, has affiliations with GlaxoSmithKline, Novartis, Roche/Genentech, Sanofi-Aventis, and Vaccinex (Consulting Fees); AstraZeneca, GlaxoSmithKline, Merck, Myriad, Oncothyreon, Roche/Genentech, and Sanofi-Aventis (Contracted Research).
  • Janice M. Mehnert, MD, has no affiliations with commercial interests to disclose.
RMEI, LLC
  • Sherri KramerMD, has no affiliations with commercial interests to disclose.
  • Amy Reeve has no affiliations with commercial interests relative to the content to disclose.
Postgraduate Institute for Medicine
The following PIM planners and managers, Judi Smelker-Mitchek, RN, BSN, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, and Jan Schultz, MSN, RN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
 
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
 
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 
 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
 
Estimated time to complete: 1.0 hour
Medium: Internet

FEE INFORMATION
There is no fee for this educational activity.

COMMERCIAL SUPPORT
This activity is supported by an independent educational grant from Genentech.

HOW TO RECEIVE CREDIT
By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive up to 1.0 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:
 
  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.
Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the self-assessment to receive credit for this activity. All other participants who successfully complete the self-assessment and evaluation will receive a certificate of participation.
 
COURSE VIEWING REQUIREMENTS
Supported Browsers:
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above